Document is current

Article History

Received: 29 August 2024

Accepted: 31 December 2024

First Online: 27 January 2025

Declarations

:

: Not applicable.

: Not applicable.

: C.U.C. has been a consultant and/or advisor to or has received honoraria from AbbVie, Acadia, Adock Ingram, Alkermes, Allergan, Angelini, Aristo, Biogen, Boehringer-Ingelheim, Bristol Myers Squibb, Cardio Diagnostics, Cerevel, CNX Therapeutics, Compass Pathways, Darnitsa, Delpor, Denovo, Gedeon Richter, Hikma, Holmusk, Intra-Cellular Therapies, Jamjoom Pharma, Janssen/J&J, Karuna, LB Pharma, Lundbeck, MedInCell, Merck, Mindpax, Mitsubishi Tanabe Pharma, Maplight, Mylan, Neumora Therapeutics, Neurocrine, Neurelis, Newron, Noven, Novo Nordisk, Otsuka, PPD Biotech, Recordati, Relmada, Reviva, Rovi, Sage, Saladax, Seqirus, SK Life Science, Sumitomo Pharma America, Sunovion, Sun Pharma, Supernus, Tabuk, Takeda, Teva, Tolmar, Vertex, Viatris, and Xenon Pharmaceuticals. He provided expert testimony for Janssen and Otsuka. He served on a Data Safety Monitoring Board for Compass Pathways, Denovo, Lundbeck, Relmada, Reviva, Rovi, Supernus, and Teva. He has received grant support from Janssen and Takeda. He received royalties from UpToDate and is also a stock option holder of Cardio Diagnostics, Kuleon Biosciences, LB Pharma, Mindpax, and Quantic. A.J.C. has been a consultant for AbbVie, Acadia Pharmaceuticals, Alfasigma, Alkermes, Avanir, Axsome, Biogen, BioXcel Therapeutics, Bristol Myers Squibb, Cerevel, Corium, 4M Therapeutics, Intra-Cellular Therapies, Ironshore, Janssen/J&J, Karuna Therapeutics, Lundbeck, MapLight Therapeutics, Neumora, Neurocrine Biosciences, Noven, Otsuka, Relmada Therapeutics, Sage Therapeutics, Sunovion, Supernus Pharmaceuticals, Takeda, Teva, Tris Pharma, Vanda, VistaGen, and VivoSense; has received speaker/promotional honoraria from AbbVie, Acadia Pharmaceuticals, Alfasigma, Alkermes, Axsome, BioXcel Therapeutics, Corium, Intra-Cellular Therapies, Ironshore, Janssen/J&J, Lundbeck, Neurocrine Biosciences, Noven, Otsuka, Sunovion, Supernus, Takeda, Teva, Tris Pharma, and Vanda; has received research grants from Akili Interactive, Alkermes, Allergan (now AbbVie), Arbor Pharmaceuticals, Biohaven, Ironshore, KemPharm, Lilly, Lundbeck, Novartis, Otsuka, Purdue Canada, Sage Therapeutics, Sunovion, Supernus Pharmaceuticals, Takeda, and Tris Pharma; and he is a member of DSMB (Data Safety Monitoring Board) for COMPASS Pathways; and has stock options from Relmada Therapeutics and 4M Therapeutics. F.L., G.G., S.D.M., and J.B. are employees of Groupe d’analyse, Ltée, which was contracted by AbbVie. S.W.W. is a partner in Wade Outcomes Research and Consulting and a consultant for AbbVie. N.N., H-B.N., and M.P. are employees of AbbVie and may hold stock.